Multiple cytochrome P450 isoforms are involved in the generation of a pharmacologically active thiol metabolite, whereas paraoxonase 1 and carboxylesterase 1 catalyze the formation of a thiol metabolite isomer from ticlopidine

Drug Metabolism and Disposition

Volumn 42, Issue 1, 2014, Pages 141-152

  Kim, Min Jung ^a   Jeong, Eun Sook ^a   Park, Jung Soon ^a   Lee, Su Jun ^a   Ghim, Jong Lyul ^a   Choi, Chang Soo ^b   Shin, Jae Gook ^a   Kim, Dong Hyun ^a  

^a Inje University   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOTICLOPIDINE; ARYLDIALKYLPHOSPHATASE 1; BIS(4 NITROPHENYL) PHOSPHATE; CALCIUM CHLORIDE; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DIISOPROPYLPHOSPHOROFLUORIDE; DRUG METABOLITE; EDETIC ACID; ENZYME INHIBITOR; ESTERASE INHIBITOR; ISOENZYME; PIPERIDINE; RECOMBINANT ENZYME; THIOL; TICLOPIDINE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CHEMICAL BOND; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME METABOLISM; PLASMA; PLATELET AGGREGATION ASSAY; PRIORITY JOURNAL;

ADULT; ARYLDIALKYLPHOSPHATASE; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ESTERASES; HUMANS; MALE; MICROSOMES; MICROSOMES, LIVER; NADP; PLATELET AGGREGATION INHIBITORS; PROTEIN ISOFORMS; SULFHYDRYL COMPOUNDS; TICLOPIDINE; YOUNG ADULT;

EID: 84890625289     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053017     Document Type: Article

References (45)

1. Abell LM and Liu EC (2011) Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro. J Pharmacol Exp Ther 339:589-596.
2. Aleil B, Rochoux G, Monassier JP, Cazenave JP, and Gachet C (2007) Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases. J Thromb Haemost 5:879-881. (Pubitemid 46563597)
3. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, and Ellis SG, et al. (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299:1265-1276. (Pubitemid 351439073)
4. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, and La Du BN (2000) Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28:1335-1342.
5. Borowczyk K, Shih DM, and Jakubowski H (2012) Metabolism and neurotoxicity of homo-cysteine thiolactone in mice: evidence for a protective role of paraoxonase 1. J Alzheimers Dis 30:225-231.
6. Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, ten Berg JM, and Taubert D (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17:110-116.
7. Cuisset T, Morange PE, and Alessi MC (2012) Recent advances in the pharmacogenetics of clopidogrel. Hum Genet 131:653-664.
8. Dansette PM, Rosi J, Bertho G, and Mansuy D (2012a) Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol 25:348-356.
9. Dansette PM, Rosi J, Debernardi J, Bertho G, and Mansuy D (2012b) Metabolic activation of prasugrel: nature of the two competitive pathways resulting in the opening of its thiophene ring. Chem Res Toxicol 25:1058-1065.
10. Farid NA, Kurihara A, and Wrighton SA (2010) Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50: 126-142.
11. Fleming CD, Bencharit S, Edwards CC, Hyatt JL, Tsurkan L, Bai F, Fraga C, Morton CL, Howard-Williams EL, and Potter PM, et al. (2005) Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol 352:165-177. (Pubitemid 41207447)
12. Fukami T, Takahashi S, Nakagawa N, Maruichi T, Nakajima M, and Yokoi T (2010) In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human car-boxylesterase activities. Drug Metab Dispos 38:2173-2178.
13. Gonzalvo MC, Gil F, Hernández AF, Villanueva E, and Pla A (1997) Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem Biol Interact 105:169-179. (Pubitemid 27353307)
14. Gonzalvo MC, Gil F, Hernandez AF, Rodrigo L, Villanueva E, and Pla A (1998) Human liver paraoxonase (PON1): subcellular distribution and characterization. J Biochem Mol Toxicol 12: 61-69. (Pubitemid 128501118)
15. Gurbel PA, Bliden KP, Hiatt BL, and O'Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908-2913. (Pubitemid 36736631)
16. Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, and Ikeda T (2009) A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 37:2145-2152.
17. Heymann E and Krisch K (1967) Phosphoric acid-bis-(p-nitro-phenylester), a new inhibitor of microsomal carboxylesterases [article in German]. Hoppe Seylers Z Physiol Chem 348: 609-619.
18. Hioki T, Fukami T, Nakajima M, and Yokoi T (2011) Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. Drug Metab Dispos 39:1345-1352.
19. Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, and Montalescot G (2011) CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 4:422-428.
20. Ishizuka T, Fujimori I, Kato M, Noji-Sakikawa C, Saito M, Yoshigae Y, Kubota K, Kurihara A, Izumi T, and Ikeda T, et al. (2010) Human carboxymethylenebutenolidase as a bioactivat-ing hydrolase of olmesartan medoxomil in liver and intestine. J Biol Chem 285:11892-11902.
21. Johnson G and Moore SW (2000) Cholinesterase-like catalytic antibodies: reaction with substrates and inhibitors. Mol Immunol 37:707-719. (Pubitemid 32244119)
22. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, and Kurihara A (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92-99.
23. Lesesve JF, Callat MP, Lenormand B, Monconduit M, Noblet C, Moore N, Caron F, Humbert G, Stamatoullas A, and Tilly H (1994) Hematological toxicity of ticlopidine. Am J Hematol 47: 149-150.
24. Love BB, Biller J, and Gent M (1998) Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf 19:89-98. (Pubitemid 28389035)
25. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJ, and Durrington PN (1998) Serum paraoxonase (PON1) 55 and 192 polymorphism and para-oxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139:341-349. (Pubitemid 28361819)
26. Maeda A, Ando H, Asai T, Ishiguro H, Umemoto N, Ohta M, Morishima M, Sumida A, Kobayashi T, and Hosohata K, et al. (2011) Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Clin Pharmacol Ther 89: 229-233.
27. Mataix R, Ojeda E, Perez MC, and Jimenez S (1992) Ticlopidine and severe aplastic anaemia. Br J Haematol 80:125-126.
28. Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, and Ikeda T (2009a) Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica 39:836-843.
29. Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, Farid NA, and Ikeda T (2009b) Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug Metab Dispos 37:589-593.
30. Noble S and Goa KL (1996) Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Drugs Aging 8:214-232.
31. Ono K, Kurohara K, Yoshihara M, Shimamoto Y, and Yamaguchi M (1991) Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematol 37:239-242.
32. Preuss CV and Svensson CK (1996) Arylacetamide deacetylase activity towards mono-acetyldapsone. Species comparison, factors that influence activity, and comparison with 2-acetylaminofluorene and p-nitrophenyl acetate hydrolysis. Biochem Pharmacol 51:1661-1668.
33. Quinney SK, Sanghani SP, Davis WI, Hurley TD, Sun Z, Murry DJ, and Bosron WF (2005) Hydrolysis of capecitabine to 59-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther 313:1011-1016. (Pubitemid 40727004)
34. Richter RJ, Jarvik GP, and Furlong CE (2009) Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 235:1-9.
35. Sato Y, Miyashita A, Iwatsubo T, and Usui T (2012) Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver. Drug Metab Dispos 40:902-906.
36. Seo KA, Lee SJ, Kim KB, Bae SK, Liu KH, Kim DH, and Shin JG (2012) Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica 42:278-284.
37. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, and Yan B (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319: 1477-1484.
38. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, and Gibson Q, et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302: 849-857.
39. Steinhubl SR, Tan WA, Foody JM, and Topol EJ (1999) Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPIS-TENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. JAMA 281:806-810. (Pubitemid 29113740)
40. Takahashi S, Katoh M, Saitoh T, Nakajima M, and Yokoi T (2009) Different inhibitory effects in rat and human carboxylesterases. Drug Metab Dispos 37:956-961.
41. Talakad JC, Shah MB, Walker GS, Xiang C, Halpert JR, and Dalvie D (2011) Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4. Drug Metab Dispos 39:539-550.
42. Tougou K, Nakamura A, Watanabe S, Okuyama Y, and Morino A (1998) Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab Dispos 26:355-359. (Pubitemid 28201246)
43. Tuffal G, Roy S, Lavisse M, Brasseur D, Schofield J, Delesque Touchard N, Savi P, Bremond N, Rouchon MC, and Hurbin F, et al. (2011) An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost 105:696-705.
44. Williams FM (1985) Clinical significance of esterases in man. Clin Pharmacokinet 10:392-403. (Pubitemid 15242339)
45. Yin T and Miyata T (2011) Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res 128:307-316.